---
document_datetime: 2023-09-21 19:11:53
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/rapilysin-epar-procedural-steps-taken-authorisation_en.pdf
document_name: rapilysin-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.3759271
conversion_datetime: 2025-12-14 23:20:02.947875
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The company Boehringer Mannheim GmbH, Germany, submitted on 30 June 1995, an application for marketing  authorisation  to  the  European  Evaluation  Medicines  Agency  (EMEA)  for  the  medicinal product Rapilysin 10 U through the centralised procedure falling within the scope of Part A of the Annex to Council Regulation No. (EC) 2309/93.

The Rapporteur and the Co-Rapporteurs appointed by the CPMP were:

Rapporteur

Prof. D. A. Hildebrandt

## Licensing Status:

Rapilysin 10 U has been given Marketing Authorisations in the following countries outside the EU:

New Zealand Norway Slovakia Switzerland USA

## 2. Steps taken for the assessment of the product

- The  Rapporteur's  initial  Assessment  Report  was  circulated  to  all  CPMP  Members  on 30 October 1995
- The  Co-Rapporteur's  initial  Assessment  Report  was  circulated  to  all  CPMP  Members  on 30 October 1995
- The CPMP in its meeting on 19-21 December 1995 agreed on a consolidated list of questions as prepared by the Rapporteur and the Co-Rapporteur
- The  company  submitted  the  responses  to  the  CPMP  consolidated  list  of  questions  on 4 March 1996.
- The Rapporteur circulated the comments on the company's responses to the assessment report to all CPMP Members on 11 April 1996
- The Biotechnology Working Party report was forwarded to the CPMP on 13 May 1996.
- The CPMP during their meeting of 21-23 May 1996 issued a positive opinion for granting a marketing authorisation for Rapilysin 10 U.

Co-Rapporteur Dr. Jensen